focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 28.50
Bid: 28.00
Ask: 29.00
Change: 0.00 (0.00%)
Spread: 1.00 (3.571%)
Open: 28.50
High: 28.50
Low: 28.50
Prev. Close: 28.50
IKA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Fuel Cell Catalyst Patent Granted in Japan

1 May 2013 07:00

RNS Number : 6723D
Ilika plc
01 May 2013
 



 

Ilika plc

("Ilika" or the "Company")

 

Fuel Cell Catalyst Patent Granted in Japan

 

Ilika (AIM: IKA), the advanced cleantech materials company, announces that further to the granting of its patent application covering its lower cost metal alloys and their use as electro-catalysts in PEM fuel cells in the USA, it has also received notification that this patent has now been granted in Japan.

 

In a PEM fuel cell, a controlled reaction occurs between hydrogen and oxygen. This reaction requires electro-catalysts, which are currently based on the precious metal, platinum. Ilika has developed a novel platinum-free catalyst, which on a cost/performance basis, has been shown to be 70% cheaper than the current industry standard. Ilika's electro-catalysts, which were originally invented using its high throughput materials development platform at its facility in Southampton, UK, have been subsequently manufactured to Ilika's specification by a partner using an industrially-scalable process.

 

As communicated in Ilika's Trading update released in April 2013, Ilika has submitted positive cell performance data and material samples for evaluation by select automotive manufacturers based primarily in the US and Japan. Therefore, the grant of this patent in both the USA and Japan confirms that the Company has secured the intellectual property in two of the major markets in which Ilika intends to commercialise its proprietary technology.

 

Furthermore, Ilika's development partner in Taiwan has now successfully manufactured the catalyst material, which is a critical component of the PEM fuel cell, to Ilika's specification at the kilogram scale. This development progress ensures that the industrial production process can be readily transferred to any volume-manufacturing partner.

 

Ilika's patents underpin the product development work, which is being supported by the Carbon Trust through the £150,000 equity investment Ilika announced in September 2012. The Carbon Trust invested in Ilika through its Polymer Fuel Cells Challenge programme to support the commercialization of Ilika's high performing electro-catalysts for use in fuel cell vehicles. As part of the Carbon Trust's technical and commercial evaluation of the technology, Ilika submitted performance data for assessment by independent experts demonstrating the performance and stability of the catalyst. The performance data was generated in industry standard tests of membrane electrode assemblies (MEA's) carried out at an independent fuel cell testing facility. The investment from the Carbon Trust is currently supporting Ilika in having a larger quantity of the electro-catalyst made for testing by the major automotive OEMs that have expressed their interest in the technology.

 

Graeme Purdy, Chief Executive of Ilika, added:"The grant of this patent in Japan builds on the Company's IP position in the USA and is an important stepping-stone in reinforcing the commercial value of Ilika's technology in this area. From a revenue perspective, Japan continues to be the most important jurisdiction for the Company and our team there is now broadening its customer interactions for commercialising this technology".

 

 

For more information contact:

 

Ilika plc

www.ilika.com

Graeme Purdy, Chief Executive

Tel: 023 8011 1400

Steve Boydell, Finance Director

 

 

 

Numis Securities Limited

Tel: 020 7260 1000

Oliver Cardigan, Nominated Adviser

 

James Black, Corporate Broking

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus

Mob: 07980 541 893 or ilika@walbrookpr.com

Paul Cornelius

Mob: 07827 879 460 or ilika@walbrookpr.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCURANROBASOAR
Date   Source Headline
13th May 202410:16 amRNSPosting of Circular & Notice of General Meeting
10th May 20243:02 pmRNSResult of Placing
10th May 20247:00 amRNSProposed Placing and Open Offer & Notice of GM
26th Apr 20247:00 amRNSAgratas joins Goliath industrialisation programme
23rd Apr 20247:00 amRNSCapital Markets Day and Trading Update
27th Mar 20247:00 amRNSNotice of Capital Markets Day and Investor Q&A
23rd Jan 20247:00 amRNSHalf-year Report
15th Jan 20247:00 amRNS2024 Conference Schedule
14th Dec 20231:46 pmRNSAward of Share Options, Exercise of Options & TVR
13th Dec 20231:43 pmRNSHolding(s) in Company
6th Dec 20237:00 amRNSLithium-ion parity development milestone
24th Nov 20237:00 amRNSTrading Update, Notice of Results & Presentations
20th Nov 20237:00 amRNSKey Technology Development Milestone
9th Oct 20237:00 amRNSAward of Scale-up Grant Funding for Goliath
20th Sep 20233:20 pmRNSResult of AGM & Award of Executive Share Options
18th Aug 20237:00 amRNSPosting of Annual Report and Notice of AGM
4th Aug 20237:00 amRNSSigned agreement with Cirtec Medical
13th Jul 20237:00 amRNSFinal Results
16th Jun 20237:00 amRNSSenior appointment&conversion of preference shares
22nd May 20237:00 amRNSTrading Update & Notice of Results
11th May 20237:00 amRNSFirst Customer Shipments of Stereax M300 Batteries
26th Apr 20237:00 amRNSExercise of Options and Total Voting Rights
11th Apr 20237:00 amRNSFirst Customer Shipment of Stereax® Batteries
8th Mar 20234:35 pmRNSPrice Monitoring Extension
1st Mar 20237:00 amRNSAward of Share Options
31st Jan 202310:30 amRNSDirector/PDMR Shareholding
30th Jan 20232:05 pmRNSSecond Price Monitoring Extn
30th Jan 20232:00 pmRNSPrice Monitoring Extension
30th Jan 202311:05 amRNSSecond Price Monitoring Extn
30th Jan 202311:00 amRNSPrice Monitoring Extension
26th Jan 20232:05 pmRNSSecond Price Monitoring Extn
26th Jan 20232:00 pmRNSPrice Monitoring Extension
26th Jan 202311:05 amRNSSecond Price Monitoring Extn
26th Jan 202311:00 amRNSPrice Monitoring Extension
26th Jan 20239:05 amRNSSecond Price Monitoring Extn
26th Jan 20239:00 amRNSPrice Monitoring Extension
26th Jan 20237:00 amRNSAward of Grant Funding for Goliath
19th Jan 20237:00 amRNSHalf-year Report
16th Jan 20237:00 amRNSMOU signed with Cirtec Medical
9th Jan 20234:40 pmRNSSecond Price Monitoring Extn
9th Jan 20234:35 pmRNSPrice Monitoring Extension
28th Dec 20224:40 pmRNSSecond Price Monitoring Extn
28th Dec 20224:35 pmRNSPrice Monitoring Extension
28th Dec 20222:05 pmRNSSecond Price Monitoring Extn
28th Dec 20222:00 pmRNSPrice Monitoring Extension
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
16th Dec 20224:40 pmRNSSecond Price Monitoring Extn
16th Dec 20224:35 pmRNSPrice Monitoring Extension
21st Nov 20221:29 pmEQSIlika 'well positioned' to deliver battery product combination

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.